I found the call very perplexing. On the one hand, management announced it will limit future focus to pursuing 2 indications in an effort to be efficient and frugal. The hold doesn't apply to Nash or cancer. Yet, apparently no clinical trial protocols have been submitted, nor are any under contemplation as far as what was said in the call. The HIV BLA may well be irretrievably defective. And no plans were mentioned to raise money.

After covering the above state of affairs, management then included a question regarding its willingness to entertain a buyout offer as one of the few among the many proposed shareholder questions available. In doing so, Cyrus mentioned management's fiduciary obligation to act in the best interests of shareholders and the fact that shareholders would have the ultimate responsibility to approve or reject a buyout offer. I would not be shocked if some BP companies were listening to the call, and, given the absence of any specifics regarding future Nash and/or cancer clinical trials, it almost sounded as if Cyrus was saying:at this point, we will pass along ANY buyout offer to the shareholders for consideration.

As usual, I'm just guessing and, admittedly my CYDY guessing average has been well below the Mendoza line over the last year.